Lindemann A, Oster W, Herrmann F, Mertelsmann R
Abteilung für Hämatologie, Universität Mainz.
Arzneimittelforschung. 1988 Mar;38(3A):466-9.
The use of recombinant cytokines offers a new dimension in cancer treatment. While the effects of cytotoxic chemotherapy are relatively nonspecific and affecting all rapidly proliferating tissues, these hormone-like, physiologically produced substances are able to modulate tumor-host interactions and in addition may interact with pathogenetically relevant disturbances in growth related cellular functions. The latter principle seems to be of major importance for the impressive results of interferon alfa treatment in hairy cell leukemia. The expected anti-tumor effects of tumor necrosis factor alfa and of interleukin-2 activated killer cells, however, have only been observed in occasional patients, most of them with rare tumors. A more immediately promising therapeutic approach seems to be at hand with the hemopoietic growth factors. They are able to stimulate the non-specific system of host defense as well as the hemopoietic progenitor cell compartment, relevant for reconstitution after aplasiogenic chemotherapy and bone marrow transplantation and thus in near future could be of great importance in the treatment of tumor diseases.
重组细胞因子的应用为癌症治疗开辟了新的领域。细胞毒性化疗的效果相对非特异性，会影响所有快速增殖的组织，而这些类似激素、由生理产生的物质能够调节肿瘤与宿主的相互作用，此外还可能与生长相关细胞功能中与发病机制相关的紊乱相互作用。后一原理似乎对干扰素α治疗毛细胞白血病取得的显著效果至关重要。然而，肿瘤坏死因子α和白细胞介素-2激活的杀伤细胞预期的抗肿瘤作用仅在少数患者中观察到，其中大多数患有罕见肿瘤。造血生长因子似乎提供了一种更具立竿见影前景的治疗方法。它们能够刺激宿主防御的非特异性系统以及造血祖细胞区室，这对于再生障碍性化疗和骨髓移植后的重建至关重要，因此在不久的将来可能在肿瘤疾病治疗中具有重要意义。
